A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Business description not available.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 499M | 499M | 392M | 331M | 328M | 237M |
| Net Income | 23M | 23M | 23M | 23M | 22M | 14M |
| EPS | $0.00 | - | - | $0.00 | $0.00 | - |
| Free Cash Flow | 18M | 18M | 38M | 32M | 15M | 14M |
| ROIC | 10.6% | 5.4% | 5.8% | 4.8% | 5.5% | 3.5% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 1.15 | 0.97 | 0.84 | 0.90 | 0.79 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 48M | 48M | 43M | 33M | 33M | 18M |
| Operating Margin | 9.5% | 9.5% | 10.9% | 10.1% | 10.2% | 7.5% |
| ROE | 6.7% | 7.0% | 7.3% | 7.5% | 8.2% | 5.8% |
| Shares Outstanding | 0M | - | - | 8,930M | 8,973M | - |
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 237M | 328M | 331M | 392M | 499M | 499M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | 18M | 33M | 33M | 43M | 48M | 48M |
| Op. Margin | 7.5% | 10.2% | 10.1% | 10.9% | 9.5% | 9.5% |
| Net Income | 14M | 22M | 23M | 23M | 23M | 23M |
| Net Margin | 5.7% | 6.8% | 6.8% | 5.8% | 4.7% | 4.7% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | 3.5% | 5.5% | 4.8% | 5.8% | 5.4% | 10.6% |
| ROE | 5.8% | 8.2% | 7.5% | 7.3% | 7.0% | 6.7% |
| ROA | 2.6% | 3.5% | 3.2% | 2.9% | 2.6% | 2.6% |
| Cash Flow | ||||||
| Op. Cash Flow | 26M | 43M | 46M | 54M | 38M | 38M |
| Free Cash Flow | 14M | 15M | 32M | 38M | 18M | 18M |
| Owner Earnings | 13M | 25M | 27M | 31M | 10M | 10M |
| CapEx | 13M | 27M | 15M | 17M | 20M | 20M |
| Maint. CapEx | 13M | 18M | 19M | 23M | 27M | 27M |
| Growth CapEx | 0 | 9.1M | 0 | 0 | 0 | 0 |
| D&A | 13M | 18M | 19M | 23M | 27M | 27M |
| CapEx/OCF | 47.9% | 63.9% | 31.5% | 30.9% | 52.3% | 52.3% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 532K | 3.7M | 3.1M | 1.6M | 547K | 547K |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||
| Net Debt | 157M | 229M | 215M | 291M | 373M | -29M |
| Cash & Equiv. | 28M | 49M | 33M | 25M | 29M | 29M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.79 | 0.90 | 0.84 | 0.97 | 1.15 | 0.00 |
| Interest Coverage | 5.6 | 6.3 | 7.0 | 3.6 | 3.0 | 3.0 |
| Equity | 233M | 308M | 294M | 325M | 348M | 348M |
| Total Assets | 528M | 739M | 680M | 864M | 919M | 919M |
| Total Liabilities | 295M | 432M | 386M | 538M | 559M | 559M |
| Intangibles | N/A | N/A | N/A | 238M | 304M | 304M |
| Retained Earnings | N/A | N/A | N/A | N/A | N/A | N/A |
| Working Capital | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Per Share Data | ||||||
| EPS | N/A | 0.00 | 0.00 | N/A | N/A | 0.00 |
| Owner EPS | N/A | 0.00 | 0.00 | N/A | N/A | N/A |
| Book Value | N/A | 0.03 | 0.03 | N/A | N/A | 0.00 |
| Cash Flow/Share | N/A | 0.00 | 0.01 | N/A | N/A | 0.00 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | N/A | 9.0B | 8.9B | N/A | N/A | 0.0M |
| Valuation | ||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | 8.8 | N/A | N/A | 6.8 | 7.8 | -0.6 |
| Price/Book | N/A | 175.1 | 121.7 | N/A | N/A | N/A |
| Price/Sales | N/A | 164.3 | 108.0 | N/A | N/A | N/A |
| FCF Yield | N/A | 0.0% | 0.1% | N/A | N/A | N/A |
| Market Cap | 0 | 53.9B | 35.8B | 0 | 0 | 0 |
| Avg. Price | 5.73 | 6.34 | 4.54 | 4.46 | 5.55 | 4.75 |
| Year-End Price | 6.47 | 6.00 | 4.01 | 5.21 | 5.60 | 4.75 |
GAROFALO HEALTH CARE passes 0 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average ROIC is 5.0%. At current prices, the estimated annualized return to fair value is +0.0%.
GAROFALO HEALTH CARE (GHC-MI) has a current P/E ratio of 1900.0, compared to its historical median P/E of 15.0. The stock is currently considered Expensive based on its historical valuation range.
GAROFALO HEALTH CARE (GHC-MI) has a 5-year average return on invested capital (ROIC) of 5.0%. This is below average and may indicate limited pricing power.
GAROFALO HEALTH CARE (GHC-MI) does not currently pay a regular dividend.
Based on historical P/E analysis, GAROFALO HEALTH CARE (GHC-MI) appears expensive. The current P/E of 1900.0 is 12567% above its historical median of 15.0. The estimated fair value CAGR (P/E method) is 0.0%.
GAROFALO HEALTH CARE (GHC-MI) reported annual revenue of $499 million in its most recent fiscal year, based on SEC EDGAR filings.
GAROFALO HEALTH CARE (GHC-MI) has a net profit margin of 4.7%. This is a modest margin.
GAROFALO HEALTH CARE (GHC-MI) generated $18 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
GAROFALO HEALTH CARE (GHC-MI) has a debt-to-equity ratio of 1.15. This indicates moderate leverage.
GAROFALO HEALTH CARE (GHC-MI) has a return on equity (ROE) of 7.0%. This indicates moderate shareholder returns.
The Ledger Terminal provides 5 years of financial data for GAROFALO HEALTH CARE (GHC-MI), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.